TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03229824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antiseptic occlusive dressing group
Description: A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
Study: NCT05316831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Pneumococcal polysaccharides conjugated to CRM197 carrier protein
Study: NCT04267172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surgical simulation training in primary Total Hip Arthroplasty
Description: The simulation-based and cognitive learning package will be delivered to a randomised sub-group of 50% of the Surgical Residents recruited into this study. This will be delivered in a supervised non-clinical setting within a dedicated University-owned simulation laboratory over a 4-week period for between 1 to 2 hours per week, over 3 to 4 consecutive but separate six-month placements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention: Surgical Resident Control Group
Description: Control Group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention: Consultant and Fellow Comparator Group
Description: Comparator Group
Study: NCT02242305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine Butylbromide - Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine Butylbromide - Capsule
Study: NCT02411175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% ethanol
Study: NCT02242305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00519415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tongue plate
Description: A functional appliance use for maxillary protraction.It has two adams clasp and two C clasp to retained the appliance and long palatal plate in the canine area which cages the tongue and transfer the force of the tongue during physiological activity to the upper arch. It has posterior bite plate and middle screw for maxillary expansion.It should be used all the time except meal time and brushing the teeth,the acrylic appliance makes specifically for the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facemask
Description: An extraoral appliance use for treatment of maxillary deficiency in growing patients.It takes anchorage from chin and forehead, it has removable intraoral appliance with hooks for elastics that exerted a force of 300 gr.It should be used 14 hours a day.
Study: NCT00861315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized amikacin
Description: Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous amikacin
Description: 20 mg/Kg amikacin are administred intravenousely once a day during three days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo nebulization
Description: 0.9% saline solution is nebulized once a day during three days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo infusion
Description: 0.9% saline is administered intravenousely once a day during three days
Study: NCT00718887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Adefovir/Entecavir
Description: Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks
Study: NCT03265431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-TPP
Description: Imaging with 18-F-TPP (18F-BFPET)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-TPP
Description: Imaging with 18-F-TPP (18F-BFPET)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-TPP
Description: Imaging with 18-F-TPP (18F-BFPET)
Study: NCT00969735

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein cryoablation
Description: A deflectable over-the-wire cryoablation balloon catheter (Arctic Front®) will be inflated and be positioned at each PV antrum. Then, cryoenergy will be delivered for 300 seconds. During cryoablation of the right PVs, the right phrenic nerve integrity will be monitored by the observation of right hemi-diaphragm contractions in response to right phrenic nerve pacing at the superior vena cava. Once the 4 PVs are cryoablated, the Arctic Front® catheter will be replaced by a decapolar PV mapping circular catheter (Lasso®, Biosense Webster, Diamond Bar, California, EEUU) to evaluate PV conduction. A second cryoablation application may be delivered at each PV, if necessary. Crossover to RF ablation to complete PV isolation is discouraged.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein radiofrequency ablation
Description: Ablation approach is ostial electrical isolation of all PVs with simultaneous use of the CARTO® electroanatomic mapping system (Biosense Webster, Tirat-Ha-Carmel, Israel). PV isolation will be performed by delivering RF energy at ostial sites with earliest PV potentials. Flow rate during the RF applications will be set at 15 mL/min (baseline 2 mL/min). Temperature and power limits will be set at 45ºC and 35 W. It will be allowed a 5 W reduction in power limit setting for small PVs (angiographic supero-inferior diameter \> 12 mm), and a 5 W increase in areas located away from the esophagus, and for focal applications at sites resistant to ablation or recurrent gaps. The end-point of ablation will be to achieve bidirectional PV conduction block.
Study: NCT02768428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-Audio Media
Description: each arm spends 15 mins for watching the video or study the handbooks
Study: NCT00492739

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vaccination with VZV vaccine
Description: Varicella vaccination 2 doses 2 months apart.
Study: NCT03594422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQP1351
Description: HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQP1351
Description: HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.
Study: NCT02037568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fPER
Description: Briefly in order, the sessions will include: 1) Overview and introduction to stress management, 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs, and 8) Getting the support they need, modeled after a successful intervention for patient groups. Manualization is crucial for successful wider implementation. Sessions 9 and 10 will provide booster sessions in which the interventionist will assess current challenges for the caregiver, provide review, and emphasize further coping skills training that might assist the caregiver in managing current stressors such as coping with the new normal.
Study: NCT03837015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estring Vaginal Ring
Description: Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estring Vaginal Ring
Description: Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estring Vaginal Ring
Description: Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RepHresh Pro-B
Description: Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RepHresh Pro-B
Description: Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RepHresh Pro-B
Description: Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally
Study: NCT01159314

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baerveldt Device surgical Procedure
Description: Implant surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baerveldt Device surgical Procedure
Description: Implant surgery
Study: NCT03577054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBB Prompt
Description: Mobile app developed through user-centred design in phase 1 of this study

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low-Dose High Frequency training
Description: Participants will be encouraged to practice their HBB skills daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Dose High Frequency training
Description: Participants will be encouraged to practice their HBB skills daily
Study: NCT04617847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120101
Description: WVE-120101 is a stereopure antisense oligonucleotide (ASO). It is administered monthly via intrathecal injection.
Study: NCT03811743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brenner FIT
Description: Brenner FIT pediatric weight management program enrollment. an interdisciplinary, family-based pediatric weight management clinic based upon the Familial Approach to Treatment of Childhood Obesity. Patients are referred by a physician for obesity or overweight with a weight-related comorbidity. Treatment teams are comprised of a pediatrician, counselor, dietitian, and physical activity specialist, with others (e.g., social workers, physical therapists) as needed. The entire family is encouraged to attend all aspects of the treatment program, although only one attending caregiver is required.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: By Design
Description: Weight loss program for adults/caregivers of those enrolled in Brenner FIT. Participants in the By Design condition (adult caregivers) will be prescribed the Essentials lifestyle intervention which includes tailored dietary and physical activity goals designed to achieve 1-2 lbs./week of weight loss, provided by a multidisciplinary team of medical providers, dietitians, behaviorists, and exercise specialists. A daily calorie restriction of 500 kcal/day is prescribed based on estimates of total energy expenditure (TEE) obtained from a measured resting metabolic rate (RMR) prior to enrollment.
Study: NCT02030795

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Disconnection group
Description: The blocker cuff was deflated, the single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse, then the cuff was re-inflated with the same amount of air as determined previously and the ventilator was reconnected to the single lumen tube

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bronchial Suction group
Description: The barrel part of a 1-mL insulin syringe was attached to the suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
Study: NCT04438642

Intervention type: PROCEDURE
Group type: OTHER
Intervention: shoulder finishline
Description: tooth will be prepared having shoulder finishline.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: butt joint with bevel
Description: tooth will be prepared having butt joint with bevel finishline.
Study: NCT03049891

Intervention type: OTHER
Intervention: Data abstraction
Description: The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.

Intervention type: OTHER
Intervention: Data abstraction
Description: The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.

Intervention type: OTHER
Intervention: Tracing questionnaire
Description: The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
Study: NCT03811743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordination
Description: This component adds four additional strategies: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. This innovative approach will seek to employ components of motivation and communication theories to increase self-monitoring, positive communication, problem solving, and social support to increase healthy physical activity and eating behaviors to increase the effectiveness of the weight loss programs beyond gains observed in matched controls.~Essentials (adults), with four additional components: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment
Study: NCT03049891

Intervention type: OTHER
Intervention: Tier.net
Description: For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.

Intervention type: OTHER
Intervention: Tier.net
Description: For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.

Intervention type: OTHER
Intervention: Tier.net
Description: For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
Study: NCT02892357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment group
Description: Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.
Study: NCT00917553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline monohydrate
Description: 50 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose Placebo Capsule
Study: NCT04239807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group 1 GALILEO WBV
Description: 3 month home based WBV training
Study: NCT02762786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: musical training
Description: The subjects in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation.
Study: NCT04239807

Intervention type: DEVICE
Group type: OTHER
Intervention: Group 1 GALILEO WBV
Description: 3 month home based WBV training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2 Control
Description: Training on the floor without WBV

Intervention type: OTHER
Group type: OTHER
Intervention: Group 2 Control
Description: Training on the floor without WBV
Study: NCT05316831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Pneumococcal polysaccharides conjugated to CRM197 carrier protein

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Pneumococcal polysaccharides conjugated to CRM197 carrier protein

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: Pneumococcal polysaccharides conjugated to CRM197 carrier protein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPSV23
Description: Pneumococcal polysaccharides
Study: NCT01654224

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Inactivated Influenza Vaccine
Description: 0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Inactivated Influenza Vaccine
Description: 0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin
Study: NCT01594424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8mg/kg on Days 0, 15, 30, 45, 75, 105, 119, 135, 149, and 180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin
Description: All HS who meet criteria for desensitization will receive IVIG 10% (2.0 g/kg \[maximum 140 g per dose\] on days 1 and 30).
Study: NCT00754273

Intervention type: OTHER
Intervention: etest susceptability testing
Description: E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
Study: NCT00453635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 75mg/m\^2 IV on day 1 every 3 weeks for 6 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks
Study: NCT00453635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine at the dose of 60mg/m\^2 per os,weekly
Study: NCT03758196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation instruments
Description: Renal Sympathetic Denervation from the adventitia of renal artery
Study: NCT04391790

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy and modified urinary conduit
Description: The modified retrosigmoid conduit is extended aorund 5 cm, so the left ureter does not have to cross under the mesentery wheras the presumed more robust ileal segment does.
Study: NCT02299284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia
Study: NCT03161574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Study: NCT00932165

Intervention type: DRUG
Intervention: Exemestane
Description: Aromasin® Tablets 25mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dose is 25 mg of exemestane administered orally once daily after a meal.
Study: NCT05115916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyChart Priming Message
Description: In addition to the standard FIT mailer protocol, we will send randomized participants a message via their personal health portal. Patients receive the primer approximately 1-2 weeks prior to arrival of the FIT kit, which informed patients about the incoming FIT Kit and instructed patients to complete and return the kit promptly.
Study: NCT03537313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagina douching
Description: Vaginal douches with 1000 ml of 1% povidone-iodine solution on the night before surgery and again on the morning of surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagina painting
Description: Vaginal painting of vagina stump after hysterectomy with 10% povidone-iodine solution 30 ml
Study: NCT01650272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% MInoxidil milky lotion
Description: Patient receive 5% MInoxidil milky lotion (Butylene glycol solvent)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Minoxidil solution
Description: Patient receive 5% Minoxidil solution (Propylene glycol solvent )
Study: NCT04311463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine hydrochloride
Description: Paroxetine hydrochloride will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine hydrochloride
Description: Paroxetine hydrochloride will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAXIL (Paroxetine hydrochloride )
Description: PAXIL will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAXIL (Paroxetine hydrochloride )
Description: PAXIL will be administered.
Study: NCT01780753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
Study: NCT01112111

Intervention type: DRUG
Intervention: mode of gonadotropin administration
Description: Low dose step-up administration Step down administration sequential administration

Intervention type: DRUG
Intervention: mode of gonadotropin administration
Description: Low dose step-up administration Step down administration sequential administration

Intervention type: DRUG
Intervention: mode of gonadotropin administration
Description: Low dose step-up administration Step down administration sequential administration
Study: NCT01599741

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology.
Description: Digital Subtraction Angiography (DSA) of iliac artery with reduced dose settings (83% dose reduction expected) in combination with novel X-ray imaging technology.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Normal dose DSA with conventional X-ray imaging technology
Description: Digital Subtraction Angiography (DSA) of iliac artery with normal dose settings in combination with conventional X-ray imaging technology.
Study: NCT04391790

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystectomy and standard urinary conduit ad modum Bricker
Description: The conduit is constructed using approximately 15 cm of terminal ileum and placed in the right side of the abdomen. In order for the left ureter to reach the conduit, it is mobilized behind the sigmoideum to the conduit.
Study: NCT04784468

Intervention type: OTHER
Intervention: No intervention
Description: Case-control design, one single investigation
Study: NCT01616173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: IV dexamethsone 8mg in 50mL (diluted in NS)